Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance

British Journal of Cancer

Volumn 111, Issue 8, 2014, Pages 1581-1589

  Ganapathi, S K ^a   Beggs, A D ^b   Hodgson, S V ^b   Kumar, D ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GAMMA INTERFERON; PRIMER DNA; TUMOR NECROSIS FACTOR ALPHA;

ADENOCARCINOMA; COLORECTAL TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MALE; MICROSATELLITE INSTABILITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL;

ADENOCARCINOMA; BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA PRIMERS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; MALE; MICROSATELLITE INSTABILITY; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908867157     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.477     Document Type: Article

References (49)

1. Balkwill F (2006) TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25: 409-416.
2. Blankenstein T, Qin ZH, Uberla K, Muller W, Rosen H, Volk HD, Diamantstein T (1991) Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 173: 1047-1052.
3. Brandacher G, Winkler C, Schroecksnadel K, Margreiter R, Fuchs D (2006) Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr Drug Metab 7: 599-612.
4. Chen X, BaumelM, Mannel DN, Howard OM, Oppenheim JJ (2007) Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4CD25 T regulatory cells. J Immunol 179: 154-161.
5. Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, Torkington J, Rees BI, Williams GT, Gallimore AM, Godkin AJ (2006) CD4CD25FOXP3 regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 1: e129.
6. Coffer PJ, Burgering BM (2004) Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 4: 889-899.
7. Curiel TJ (2007) Tregs and rethinking cancer immunotherapy. J Clin Invest 117: 1167-1174.
8. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
9. Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, Kirkpatrick N, Gedye C, Moss D, Ng SP, MacGregor D, Davis ID, Cebon J, Chen W (2008) The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 68: 3001-3009.
10. Evans C, Morrison I, Heriot AG, Bartlett JB, Finlayson C, Dalgleish AG, Kumar D (2006) The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer 94: 1412-1419.
11. Evans CF, Galustian C, Bodman-Smith M, Dalgleish AG, Kumar D (2010) The effect of colorectal cancer upon host peripheral immune cell function. Colorectal Dis 12: 561-569.
12. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4CD25 regulatory T cells. Nat Immunol 4: 330-336.
13. Galizia G, Lieto E, De Vita F, Romano C, Orditura M, Castellano P, Imperatore V, Infusino S, Catalano G, Pignatelli C (2002) Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res 22: 473-482.
14. Grunfeld C (2002) Leptin and the immunosuppression of malnutrition. J Clin Endocrinol Metab 87: 3038-3039.
15. Harrison JC, Dean PJ, el-Zeky F, Vander Zwaag R (1994) From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol 25: 498-505.
16. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 82: 1009-1012.
17. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, Grutzmann R, Pilarsky C, Ungefroren H, Saeger HD, Kloppel G, Kabelitz D, Kalthoff H (2007) Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67: 8344-8350.
18. Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3 regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423-5434.
19. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
20. Kanazawa M, Yoshihara K, Abe H, Iwadate M, Watanabe K, Suzuki S, Endoh Y, Takita K, Sekikawa K, Takenoshita S, Ogata T, Ohto H (2005) Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients. Anticancer Res 25: 443-449.
21. Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, Rosenwald A, Tsaur I, Blaheta R, Heemann U, Germer CT, Waaga-Gasser AM, Gasser M (2013) Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One 8: e53630.
22. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S (2007) FOXP3 regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13: 902-911.
23. Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, George BD, Warren BF, Piris J, Roncador G, Fox SB, Banham AH, Cerundolo V (2007) Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 7: 7.
24. Liotta LA, Kleinerman J, Saidel GM (1974) Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34: 997-1004.
25. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
26. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D (2006) In situ analysis of FOXP3 regulatory T cells in human colorectal cancer. J Transl Med 4: 52.
27. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E, Balsari A (2009) FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27: 1746-1752.
28. Morris M, Platell C, de Boer B, McCaul K, Iacopetta B (2006) Populationbased study of prognostic factors in stage II colonic cancer. Br J Surg 93: 866-871.
29. Nakayama H, Kitayama J, Muto T, Nagawa H (2000) Characterization of intracellular cytokine profile of CD4() T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer. Jpn J Clin Oncol 30: 301-305.
30. Needham DJ, Lee JX, Beilharz MW (2006) Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem Biophys Res Commun 343: 684-691.
31. O'Hara RJ, Greenman J, MacDonald AW, Gaskell KM, Topping KP, Duthie GS, Kerin MJ, Lee PW, Monson JR (1998) Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 4: 1943-1948.
32. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS (2009) Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15: 6412-6420.
33. Pawelec G, Barnett Y, Forsey R, Frasca D, Globerson A, McLeod J, Caruso C, Franceschi C, Fulop T, Gupta S, Mariani E, Mocchegiani E, Solana R (2002) T cells and aging, January 2002 update. Front Biosci 7: d1056-d1183.
34. Petersen VC, Baxter KJ, Love SB, Shepherd NA (2002) Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 51: 65-69.
35. Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S (2004) Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 91: 469-475.
36. Polansky JK, Kretschmer K, Freyer J, Floess S, Garbe A, Baron U, Olek S, Hamann A, von Boehmer H, Huehn J (2008) DNA methylation controls Foxp3 gene expression. Eur J Immunol 38: 1654-1663.
37. Quirke P, Morris E (2007) Reporting colorectal cancer. Histopathology 50: 103-112.
38. Radhakrishnan P, Chachadi V, Lin MF, Singh R, Kannagi R, Cheng PW (2011) TNFalpha enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl-and sulfotransferase genes involved in the synthesis of selectin ligands. Biochem Biophys Res Commun 409: 436-441.
39. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B (2009) Tumor-infiltrating FOXP3 T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27: 186-192.
40. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8 tumor-infiltrating lymphocytes and a high CD8/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538-18543.
41. Sato T, Ueno H, Mochizuki H, Shinto E, Hashiguchi Y, Kajiwara Y, Shimazaki H, Hase K (2010) Objective criteria for the grading of venous invasion in colorectal cancer. Am J Surg Pathol 34: 454-462.
42. Shibata M, Nezu T, Kanou H, Abe H, Takekawa M, Fukuzawa M (2002) Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 34: 416-420.
43. Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4/CD25 regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62: 5267-5272.
44. Sullivan KE, Reddy AB, Dietzmann K, Suriano AR, Kocieda VP, Stewart M, Bhatia M (2007) Epigenetic regulation of tumor necrosis factor alpha. Mol Cell Biol 27: 5147-5160.
45. Talbot IC, Ritchie S, Leighton MH, Hughes AO, Bussey HJ, Morson BC (1980) The clinical significance of invasion of veins by rectal cancer. Br J Surg 67: 439-442.
46. Watanabe N, Niitsu Y, Neda H, Sone H, Yamauchi N, Maeda M, Urushizaki I (1988) Cytocidal mechanism of TNF: effects of lysosomal enzyme and hydroxyl radical inhibitors on cytotoxicity. Immunopharmacol Immunotoxicol 10: 109-116.
47. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9: 606-612.
48. Xue L, Lu HQ, He J, Zhao XW, Zhong L, Zhang ZZ, Xu ZF (2010) Expression of FOXP3 in esophageal squamous cell carcinoma relating to the clinical data. Dis Esophagus 23: 340-346.
49. Zou W(2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307.